impaction
发表于 2025-3-25 05:33:41
978-3-540-52613-1Springer-Verlag Berlin Heidelberg 1990
文字
发表于 2025-3-25 08:57:08
Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia,The present contribution summarizes the results of treating acute myeloid leukemia (AML) with aclarubicin (ACM) in three consecutive studies. Some of the results have recently been published elsewhere .
Engaged
发表于 2025-3-25 12:55:25
http://reply.papertrans.cn/67/6653/665209/665209_23.png
mitral-valve
发表于 2025-3-25 19:09:43
http://reply.papertrans.cn/67/6653/665209/665209_24.png
CAND
发表于 2025-3-25 22:32:58
http://reply.papertrans.cn/67/6653/665209/665209_25.png
BYRE
发表于 2025-3-26 03:26:37
http://reply.papertrans.cn/67/6653/665209/665209_26.png
mercenary
发表于 2025-3-26 05:32:46
Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A median survival times as compared to those with no change (NC) or progressive disease (PD): 22 months for responders, 3 months for nonresponders. Censored median survival was 22 months for RAEB, 14 months for RAEB-T, but only 2 months for secondary ANLL. Evaluation of risk factors gave evidence of a
FER
发表于 2025-3-26 10:10:13
http://reply.papertrans.cn/67/6653/665209/665209_28.png
滑稽
发表于 2025-3-26 16:33:35
bination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable978-3-540-52613-1978-3-642-75720-4
cortisol
发表于 2025-3-26 17:07:12
New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia